<?xml version="1.0" encoding="UTF-8"?>
<p>The plasma filgrastim concentrations, ANC, and CD34
 <sup>+</sup> cell counts over time are shown in 
 <xref ref-type="fig" rid="f2-dddt-12-2381">Figure 2</xref> and PK parameters are provided in 
 <xref rid="t1-dddt-12-2381" ref-type="table">Table 1</xref>. For both the test and reference products, plasma concentrations of filgrastim started to increase from the time of subcutaneous administration and reached 
 <italic>C</italic>
 <sub>max</sub> at 6 hours in both 5 and 10 μg/kg dose groups. After 
 <italic>t</italic>
 <sub>max</sub>, the concentrations decreased and reached nearly zero at 36 hours, with half-lives about 7 hours. In the PK analysis, primary assessment parameters (90% CIs of the ratios between the log-transformed 
 <italic>C</italic>
 <sub>max</sub> and AUC
 <sub>0–∞</sub> of the test and reference products) were within 0.8–1.25 (
 <xref rid="t1-dddt-12-2381" ref-type="table">Table 1</xref>).
</p>
